Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer (EMILIA)

10 września 2016 zaktualizowane przez: Hoffmann-La Roche

A Randomized, Multicenter, Phase III Open-label Study of the Efficacy and Safety of Trastuzumab MCC-DM1 vs. Capecitabine + Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy

This is a Phase III, randomized, multicenter, international, 2-arm, open-label clinical trial designed to compare the safety and efficacy of trastuzumab emtansine (T-DM1) with that of capecitabine + lapatinib in participants with human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancer. Participants will be treated until disease progression (PD), unmanageable toxicity, or study termination. Once disease progression is reported, all participants will be followed for survival every 3 months until death, loss to follow-up, withdrawal of consent, or study termination.

Przegląd badań

Status

Zakończony

Warunki

Interwencja / Leczenie

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

991

Faza

  • Faza 3

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

  • Bośnia i Hercegowina
      • Banja Luka, Bośnia i Hercegowina, 78000
      • Sarajewo, Bośnia i Hercegowina, 71000
  • Brazylia
      • Belo Horizonte, Brazylia, 30150-281
      • Curitiba, Brazylia, 80530-010
      • Goiania, Brazylia, 74605-070
      • Itajai, Brazylia, 88301-220
      • JAU, Brazylia, 17210-080
      • Joao Pessoa, Brazylia, 58040280
      • Porto Alegre, Brazylia, 90610-000
      • Porto Alegre, Brazylia, 91350-200
      • Porto Alegre, Brazylia, 90430-090
      • Porto Alegre - Rs, Brazylia, 90050-170
      • Rio de Janeiro, Brazylia, 20560-120
      • Rio de Janeiro, Brazylia, 22260-020
      • Santo Andre, Brazylia, 09060-870
      • Sao Paulo, Brazylia, 1323020
      • Sao Paulo, Brazylia, 01317-000
  • Bułgaria
      • Plovdiv, Bułgaria, 4000
      • Sofia, Bułgaria, 1756
      • Sofia, Bułgaria, 1784
      • Varna, Bułgaria, 9002
  • Dania
      • Herlev, Dania, 2730
      • København, Dania, 2100
      • Odense, Dania, 5000
  • Federacja Rosyjska
      • Kemerovo, Federacja Rosyjska, 650036
      • Moscow, Federacja Rosyjska, 121356
      • St Petersburg, Federacja Rosyjska, 197758
  • Filipiny
      • Diliman, Quezon City, Filipiny, 1100
      • Quezon City, Luzon, Filipiny, 1101
  • Finlandia
      • Helsinki, Finlandia, 00180
      • Tampere, Finlandia, 33520
      • Turku, Finlandia, 20520
  • Francja
      • Avignon, Francja, 84082
      • Bordeaux, Francja, 33076
      • Brest, Francja, 29609
      • Caen, Francja, 14076
      • Dijon, Francja, 21079
      • La Roche Sur Yon, Francja, 85925
      • Montpellier, Francja, 34298
      • Paris, Francja, 75248
      • Saint Brieuc, Francja, 22015
      • Saint Herblain, Francja, 44805
      • Vandoeuvre-les-nancy, Francja, 54511
  • Hiszpania
      • Barcelona, Hiszpania, 08035
      • Córdoba, Hiszpania, 14004
      • Lerida, Hiszpania, 25198
      • Madrid, Hiszpania, 28046
      • Madrid, Hiszpania, 28041
      • Santander, Hiszpania, 39008
      • Sevilla, Hiszpania, 41013
      • Valencia, Hiszpania, 46009
      • Zaragoza, Hiszpania, 50009
  • Hongkong
      • Hong Kong, Hongkong
  • Indie
      • Bangalore, Indie, 560027
      • Gurgaon, Indie, 122001
      • Kolkata, Indie, 700 053
      • New Delhi, Indie, 110029
      • Pune, Indie, 411004
  • Kanada
    • Alberta
      • Calgary, Alberta, Kanada, T2N 4N2
      • Edmonton, Alberta, Kanada, T6G 1Z2
    • British Columbia
      • Kelowna, British Columbia, Kanada, V1Y 5L3
      • Vancouver, British Columbia, Kanada, V5Z 1H5
    • Nova Scotia
      • Halifax, Nova Scotia, Kanada, B3H 2Y9
    • Ontario
      • Ottawa, Ontario, Kanada, K1H 8L6
      • Sudbury, Ontario, Kanada, J9P 3Y1
      • Toronto, Ontario, Kanada, M4N 3M5
    • Quebec
      • Greenfield Park, Quebec, Kanada, J4V 2H1
      • Montreal, Quebec, Kanada, H1T 2M4
      • Montreal, Quebec, Kanada, H3T 1E2
      • Montreal, Quebec, Kanada, H2W 1T8
  • Kolumbia
      • Bogota, Kolumbia
      • Bogota, Kolumbia, 49 00
      • Monteria, Kolumbia
  • Meksyk
      • Acapulco, Meksyk, 39670
      • Oaxaca, Meksyk, 68000
      • Toluca, Meksyk, 50180
  • Niemcy
      • Aschaffenburg, Niemcy, 63739
      • Berlin, Niemcy, 10367
      • Berlin, Niemcy, 13125
      • Berlin, Niemcy, 4169
      • Bonn, Niemcy, 53113
      • Dortmund, Niemcy, 44137
      • Freiburg, Niemcy, 79106
      • Fuerstenwalde, Niemcy, 15517
      • Hamburg, Niemcy, 20357
      • Karlsruhe, Niemcy, 76135
      • Kiel, Niemcy, 24105
      • Offenbach, Niemcy, 63069
      • Stralsund, Niemcy, 18435
  • Nowa Zelandia
      • Newtown, Nowa Zelandia, 6021
      • Palmerston North, Nowa Zelandia, 4442
  • Polska
      • Bialystok, Polska, 15-027
      • Gdansk, Polska, 80-952
      • Krakow, Polska, 31-531
      • Lublin, Polska, 20-090
      • Opole, Polska, 45-060
      • Poznan, Polska, 61-866
      • Warszawa, Polska, 02-781
  • Portugalia
      • Coimbra, Portugalia, 3000-075
      • Lisboa, Portugalia, 1649-035
      • Porto, Portugalia, 4200-072
  • Republika Korei
      • Kyunggi-do, Republika Korei, 411-769
      • Seoul, Republika Korei, 110-744
      • Seoul, Republika Korei, 120-752
      • Seoul, Republika Korei, 135-710
  • Singapur
      • Singapore, Singapur, 119074
      • Singapore, Singapur, 169610
  • Stany Zjednoczone
    • Arizona
      • Chandler, Arizona, Stany Zjednoczone, 85224
      • Tucson, Arizona, Stany Zjednoczone, 85719
    • California
      • Anaheim, California, Stany Zjednoczone, 92801
      • Anaheim, California, Stany Zjednoczone, 92807
      • Bakersfield, California, Stany Zjednoczone, 93309
      • Baldwin Park, California, Stany Zjednoczone, 91706
      • Bellflower, California, Stany Zjednoczone, 90706
      • Duarte, California, Stany Zjednoczone, 91010
      • Fontana, California, Stany Zjednoczone, 92335
      • Hayward, California, Stany Zjednoczone, 94545
      • Irvine, California, Stany Zjednoczone, 92618
      • La Jolla, California, Stany Zjednoczone, 92093
      • La Mesa, California, Stany Zjednoczone, 91942
      • Loma Linda, California, Stany Zjednoczone, 92354
      • Long Beach, California, Stany Zjednoczone, 90806
      • Los Angeles, California, Stany Zjednoczone, 90025
      • Los Angeles, California, Stany Zjednoczone, 90057
      • Los Angeles, California, Stany Zjednoczone, 90095-1772
      • Los Angeles, California, Stany Zjednoczone, 90034
      • Montebello, California, Stany Zjednoczone, 90640
      • Newport Beach, California, Stany Zjednoczone, 92660
      • Oakland, California, Stany Zjednoczone, 94611
      • Panorama City, California, Stany Zjednoczone, 91402
      • Riverside, California, Stany Zjednoczone, 92505
      • Roseville, California, Stany Zjednoczone, 95661
      • Sacramento, California, Stany Zjednoczone, 95825
      • San Diego, California, Stany Zjednoczone, 92123
      • San Diego, California, Stany Zjednoczone, 92120
      • San Francisco, California, Stany Zjednoczone, 94115
      • San Jose, California, Stany Zjednoczone, 95119
      • Santa Clara, California, Stany Zjednoczone, 95051
      • Santa Maria, California, Stany Zjednoczone, 93454
      • Santa Monica, California, Stany Zjednoczone, 90404
      • South San Francisco, California, Stany Zjednoczone, 94080
      • Thousand Oaks, California, Stany Zjednoczone, 91360
      • Vallejo, California, Stany Zjednoczone, 94589
      • Walnut Creek, California, Stany Zjednoczone, 94596
      • Woodland Hills, California, Stany Zjednoczone, 91367
    • Colorado
      • Fort Collins, Colorado, Stany Zjednoczone, 80528
    • Connecticut
      • Norwalk, Connecticut, Stany Zjednoczone, 06856
      • Norwich, Connecticut, Stany Zjednoczone, 06360
      • Stamford, Connecticut, Stany Zjednoczone, 06902
    • District of Columbia
      • Washington, District of Columbia, Stany Zjednoczone, 20010
    • Florida
      • Boca Raton, Florida, Stany Zjednoczone, 33486
      • Fernandina Beach, Florida, Stany Zjednoczone, 32034
      • Fort Myers, Florida, Stany Zjednoczone, 33916
      • Ft. Lauderdale, Florida, Stany Zjednoczone, 33316
      • Hollywood, Florida, Stany Zjednoczone, 33021
      • Jacksonville, Florida, Stany Zjednoczone, 32205
      • Jacksonville, Florida, Stany Zjednoczone, 32256
      • Jacksonville, Florida, Stany Zjednoczone, 32207
      • Jacksonville, Florida, Stany Zjednoczone, 32258
      • Kissimmee, Florida, Stany Zjednoczone, 34741
      • Lakeland, Florida, Stany Zjednoczone, 33804-1057
      • Miami, Florida, Stany Zjednoczone, 33136
      • Miami, Florida, Stany Zjednoczone, 33176
      • Miami, Florida, Stany Zjednoczone, 33133
      • Orange Park, Florida, Stany Zjednoczone, 32073
      • Pembroke Pines, Florida, Stany Zjednoczone, 33028
    • Georgia
      • Athens, Georgia, Stany Zjednoczone, 30607
      • Atlanta, Georgia, Stany Zjednoczone, 30342
      • Atlanta, Georgia, Stany Zjednoczone, 30322
      • Atlanta, Georgia, Stany Zjednoczone, 30341
      • Atlanta, Georgia, Stany Zjednoczone, 30318
      • Carrolton, Georgia, Stany Zjednoczone, 30117
      • Cartersville, Georgia, Stany Zjednoczone, 30121
      • Decatur, Georgia, Stany Zjednoczone, 30033
      • Douglasville, Georgia, Stany Zjednoczone, 30134
      • Macon, Georgia, Stany Zjednoczone, 31217
      • Marietta, Georgia, Stany Zjednoczone, 30060
    • Idaho
      • Boise, Idaho, Stany Zjednoczone, 83712
      • Meridian, Idaho, Stany Zjednoczone, 83642
      • Nampa, Idaho, Stany Zjednoczone, 83686
      • Post Falls, Idaho, Stany Zjednoczone, 83854
      • Twin Falls, Idaho, Stany Zjednoczone, 83301
    • Illinois
      • Chicago, Illinois, Stany Zjednoczone, 60612
      • Decatur, Illinois, Stany Zjednoczone, 62526
      • Effingham, Illinois, Stany Zjednoczone, 62526
      • Joliet, Illinois, Stany Zjednoczone, 60435
      • Morris, Illinois, Stany Zjednoczone, 60450
      • Peoria, Illinois, Stany Zjednoczone, 61615-7828
      • Skokie, Illinois, Stany Zjednoczone, 60076
      • Zion, Illinois, Stany Zjednoczone, 60099
    • Iowa
      • Bettendorf, Iowa, Stany Zjednoczone, 52722
    • Kansas
      • Wichita, Kansas, Stany Zjednoczone, 67214-3728
    • Kentucky
      • Paducah, Kentucky, Stany Zjednoczone, 42001
    • Louisiana
      • Covington, Louisiana, Stany Zjednoczone, 70433
      • Lafayette, Louisiana, Stany Zjednoczone, 70503
      • Marrero, Louisiana, Stany Zjednoczone, 70072
      • Metairie, Louisiana, Stany Zjednoczone, 70006
      • New Orleans, Louisiana, Stany Zjednoczone, 70115
    • Maine
      • Kittery, Maine, Stany Zjednoczone, 03904
      • Wells, Maine, Stany Zjednoczone, 04090
      • York, Maine, Stany Zjednoczone, 03909
    • Maryland
      • Baltimore, Maryland, Stany Zjednoczone, 21202
      • Baltimore, Maryland, Stany Zjednoczone, 21237
      • Bethesda, Maryland, Stany Zjednoczone, 20817
      • Rockville, Maryland, Stany Zjednoczone, 20850
    • Massachusetts
      • Boston, Massachusetts, Stany Zjednoczone, 02215
      • Boston, Massachusetts, Stany Zjednoczone, 02114
      • Boston, Massachusetts, Stany Zjednoczone, 02118
      • Boston, Massachusetts, Stany Zjednoczone, 02115
      • Burlington, Massachusetts, Stany Zjednoczone, 01805
      • Peabody, Massachusetts, Stany Zjednoczone, 01960
    • Michigan
      • Brownstown, Michigan, Stany Zjednoczone, 48183
      • Dearborn, Michigan, Stany Zjednoczone, 48126
      • Detroit, Michigan, Stany Zjednoczone, 48201
      • Detroit, Michigan, Stany Zjednoczone, 48202
      • Saint Joseph, Michigan, Stany Zjednoczone, 49085
      • West Bloomfield, Michigan, Stany Zjednoczone, 48322
    • Minnesota
      • Edina, Minnesota, Stany Zjednoczone, 55414
      • Maplewood, Minnesota, Stany Zjednoczone, 55109
      • Minneapolis, Minnesota, Stany Zjednoczone, 55454
      • Saint Louis Park, Minnesota, Stany Zjednoczone, 55426
      • Saint Paul, Minnesota, Stany Zjednoczone, 55101
      • St. Louis Park, Minnesota, Stany Zjednoczone, 55426
    • Missouri
      • Joplin, Missouri, Stany Zjednoczone, 64804
      • Kansas City, Missouri, Stany Zjednoczone, 64111
      • Saint Louis, Missouri, Stany Zjednoczone, 63110
      • Saint Peters, Missouri, Stany Zjednoczone, 63110
      • St. Louis, Missouri, Stany Zjednoczone, 63141
      • St. Peters, Missouri, Stany Zjednoczone, 63376
    • Montana
      • Missoula, Montana, Stany Zjednoczone, 59802
    • Nebraska
      • Omaha, Nebraska, Stany Zjednoczone, 68114
    • Nevada
      • Henderson, Nevada, Stany Zjednoczone, 89052
    • New Jersey
      • Cherry Hill, New Jersey, Stany Zjednoczone, 08002
      • Hackensack, New Jersey, Stany Zjednoczone, 07601
      • Morristown, New Jersey, Stany Zjednoczone, 07962
      • Parsippany, New Jersey, Stany Zjednoczone, 07054
      • Voorhees, New Jersey, Stany Zjednoczone, 08043
    • New Mexico
      • Santa Fe, New Mexico, Stany Zjednoczone, 87505
    • New York
      • Brockport, New York, Stany Zjednoczone, 14420
      • Canandaigua, New York, Stany Zjednoczone, 14424
      • Fresh Meadows, New York, Stany Zjednoczone, 11366
      • Geneva, New York, Stany Zjednoczone, 14456
      • Greece, New York, Stany Zjednoczone, 14626
      • Lake Success, New York, Stany Zjednoczone, 11042
      • Mount Kisco, New York, Stany Zjednoczone, 10549
      • Rochester, New York, Stany Zjednoczone, 14626
      • Stony Brook, New York, Stany Zjednoczone, 11794
    • North Carolina
      • Charlotte, North Carolina, Stany Zjednoczone, 28203
      • Durham, North Carolina, Stany Zjednoczone, 27710
      • Hickory, North Carolina, Stany Zjednoczone, 28602
      • Kinston, North Carolina, Stany Zjednoczone, 28501
      • Washington, North Carolina, Stany Zjednoczone, 27889
    • Ohio
      • Cleveland, Ohio, Stany Zjednoczone, 44195
      • Cleveland, Ohio, Stany Zjednoczone, 44106
      • Columbus, Ohio, Stany Zjednoczone, 43215
      • Columbus, Ohio, Stany Zjednoczone, 43219
      • Columbus, Ohio, Stany Zjednoczone, 43228
      • Middletown, Ohio, Stany Zjednoczone, 45042
      • Newark, Ohio, Stany Zjednoczone, 43055
      • Sandusky, Ohio, Stany Zjednoczone, 44870
    • Oregon
      • Portland, Oregon, Stany Zjednoczone, 97227
    • Pennsylvania
      • Philadelphia, Pennsylvania, Stany Zjednoczone, 19124
      • Philadelphia, Pennsylvania, Stany Zjednoczone, 19106
      • Pittsburgh, Pennsylvania, Stany Zjednoczone, 15232
      • Pittsburgh, Pennsylvania, Stany Zjednoczone, 15213
    • Rhode Island
      • East Providence, Rhode Island, Stany Zjednoczone, 02915
    • South Carolina
      • Columbia, South Carolina, Stany Zjednoczone, 29210
      • North Charleston, South Carolina, Stany Zjednoczone, 29425
    • Tennessee
      • Memphis, Tennessee, Stany Zjednoczone, 38120
      • Nashville, Tennessee, Stany Zjednoczone, 37203
    • Texas
      • Austin, Texas, Stany Zjednoczone, 78731
      • Bryan, Texas, Stany Zjednoczone, 77802
      • Cypress, Texas, Stany Zjednoczone, 77429
      • Dallas, Texas, Stany Zjednoczone, 75230
      • El Paso, Texas, Stany Zjednoczone, 79902
      • Houston, Texas, Stany Zjednoczone, 77090
      • Shenandoah, Texas, Stany Zjednoczone, 77384
      • Temple, Texas, Stany Zjednoczone, 76501
    • Virginia
      • Fairfax, Virginia, Stany Zjednoczone, 22031
    • Washington
      • Gig Harbor, Washington, Stany Zjednoczone, 98332
      • Lakewood, Washington, Stany Zjednoczone, 98499
      • Puyallup, Washington, Stany Zjednoczone, 98372
      • Tacoma, Washington, Stany Zjednoczone, 98405
    • Wisconsin
      • Milwaukee, Wisconsin, Stany Zjednoczone, 53226
      • Wausau, Wisconsin, Stany Zjednoczone, 54401
  • Szwajcaria
      • Luzern, Szwajcaria, 6004
      • St. Gallen, Szwajcaria, 9007
  • Szwecja
      • Eskilstuna, Szwecja, 63188
      • Gaelve, Szwecja, 80187
      • Goteborg, Szwecja, 40036
  • Słowenia
      • Ljubljana, Słowenia, 1000
  • Tajwan
      • Kaohsung, Tajwan, 883
      • Taichung, Tajwan, 404
      • Taichung, Tajwan, 407
      • Taipei, Tajwan, 112
      • Taoyuan, Tajwan, 333
  • Włochy
      • Aviano, Włochy, 33081
      • Bologna, Włochy, 40138
      • Candiolo, Włochy, 10060
      • Genova, Włochy, 16132
      • Meldola, Włochy, 47014
      • Milano, Włochy, 20133
      • Milano, Włochy, 20141
      • Napoli, Włochy, 80131
      • Negrar, Włochy, 37024
      • Pisa, Włochy, 56100
      • Reggio Emilia, Włochy, 42100
      • Roma, Włochy, 00168
      • Rozzano, Włochy, 20089
      • Sassari, Włochy, 07100
      • Terni, Włochy, 05100
  • Zjednoczone Królestwo
      • Bournemouth, Zjednoczone Królestwo, BH7 7DW
      • Cardiff, Zjednoczone Królestwo, CF14 2TL
      • Denbigh, Zjednoczone Królestwo, LL18 5UJ
      • London, Zjednoczone Królestwo, SE1 7EH
      • London, Zjednoczone Królestwo, SW3 6JJ
      • Manchester, Zjednoczone Królestwo, M20 4BX
      • New Castle Upon Tyne, Zjednoczone Królestwo, NE7 7DN
      • Northwood, Zjednoczone Królestwo, HA6 2RN
      • Poole, Zjednoczone Królestwo, BH15 2JB
      • Preston, Zjednoczone Królestwo, PR2 9HT
      • Romford, Zjednoczone Królestwo, RM7 0AG
      • Sutton, Zjednoczone Królestwo, SM2 5PT
      • Weston Super Mare, Zjednoczone Królestwo, BS23 4TQ

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • HER2 status must be prospectively, centrally tested and be HER2-positive based on central laboratory assay results
  • Histologically or cytologically confirmed invasive breast cancer
  • Prior treatment for breast cancer in the adjuvant, unresectable, locally advanced, or metastatic setting must include both a taxane, alone or in combination with another agent, and trastuzumab, alone or in combination with another agent
  • Documented progression (which occur during or after most recent treatment or within 6 months after completing of adjuvant therapy) of incurable, unresectable, locally advanced or metastatic breast cancer, defined by the investigator
  • Measurable and/or nonmeasurable disease; participants with central nervous system-only disease are excluded
  • Cardiac ejection fraction greater than or equal to (>/=) 50 percent (%) by either echocardiogram or multi-gated acquisition scan
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • For women of childbearing potential and men with partners of childbearing potential, agreement to use a highly effective, non-hormonal form of contraception; contraception use should continue for the duration of the study treatment and for at least 6 months after the last dose of study treatment

Exclusion Criteria:

  • History of treatment with trastuzumab emtansine
  • Prior treatment with lapatinib or capecitabine
  • Peripheral neuropathy of Grade >/= 3 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 3.0
  • History of other malignancy within the last 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage 1 uterine cancer, synchronous or previously diagnosed HER2-positive breast cancer, or cancers with a similar curative outcome as those mentioned above
  • History of receiving any anti-cancer drug/biologic or investigational treatment within 21 days prior to randomization except hormone therapy, which could be given up to 7 days prior to randomization; recovery of treatment-related toxicity consistent with other eligibility criteria
  • History of radiation therapy within 14 days of randomization
  • Brain metastases that are untreated, symptomatic, or require therapy to control symptoms, as well as any history of radiation, surgery, or other therapy, including steroids, to control symptoms from brain metastases within 2 months (60 days) of randomization
  • History of symptomatic congestive heart failure or serious cardiac arrhythmia requiring treatment
  • History of myocardial infarction or unstable angina within 6 months of randomization
  • Current dyspnea at rest due to complications of advanced malignancy or current requirement for continuous oxygen therapy
  • Current severe, uncontrolled systemic disease (for example, clinically significant cardiovascular, pulmonary, or metabolic disease)
  • Pregnancy or lactation
  • Current known active infection with human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus
  • Presence of conditions that could affect gastrointestinal absorption: Malabsorption syndrome, resection of the small bowel or stomach, and ulcerative colitis
  • History of intolerance (such as Grade 3-4 infusion reaction) to trastuzumab
  • Known hypersensitivity to 5-fluorouracil or known dihydropyrimidine dehydrogenase deficiency
  • Current treatment with sorivudine or its chemically related analogs, such as brivudine

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Trastuzumab emtansine
Participants will receive trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenous (IV) infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle until disease progression (PD) (as assessed by the investigator), unmanageable toxicity, or study termination.
Lek: Trastuzumab emtansine
Trastuzumab emtansine 3.6 mg/kg IV infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle.
Inne nazwy:
  • RO5304020
  • T-DM1
  • Trastuzumab-MCC-DM1
Aktywny komparator: Lapatinib + Capecitabine
Participants will receive lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle + capecitabine 1000 milligrams per square meter (mg/m^2) orally twice daily on Days 1-14 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination. Eligible participants will cross over to receive trastuzumab emtansine if second interim analysis demonstrates statistically significant overall survival benefit in favor of trastuzumab emtansine.
Lek: Lapatinib
Lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle.
Inne nazwy:
  • Tykerb
  • Tyverb
Lek: Capecitabine
Capecitabine 1000 mg/m^2 orally twice daily on Days 1-14 of each 21-day treatment cycle.
Inne nazwy:
  • Xeloda

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Percentage of Participants With PD or Death as Assessed by an Independent Review Committee (IRC)
Ramy czasowe: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
PD was assessed by an IRC using modified Response Evaluation Criteria in Solid Tumors (RECIST). All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as target lesions (TLs) and recorded at baseline. TLs should be selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements either by imaging or clinically. A sum of the longest diameter for all TLs was calculated as baseline sum longest diameter (SLD). All other lesions (or sites of disease) should be identified as non-TLs and recorded at baseline. PD for TLs was defined as greater than or equal to (>/=) 20 percent (%) increase in SLD, taking as reference smallest SLD recorded since treatment started or appearance of 1 or more new lesions. PD for non-TLs was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Percentage of Participants with PD by IRC or death from any cause was reported.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Progression-free Survival (PFS) as Assessed by an IRC (Co-primary Endpoint)
Ramy czasowe: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Tumor response was assessed by an IRC according to modified RECIST. All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs (on the basis of their size and their suitability for accurate repeated measurements either by imaging or clinically) and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. All other lesions were identified as non-TLs and recorded at baseline. PD for TLs: >/= 20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or appearance of 1 or more new lesions. PD for non-TLs: appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. PFS: time from randomization to first documented PD by IRC or death from any cause (whichever occurred earlier). The median duration of PFS was estimated using Kaplan-Meier method. The 95% confidence interval (CI) was computed using the method of Brookmeyer and Crowley.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Percentage of Participants Who Died: Second Interim Analysis
Ramy czasowe: From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
The percentage of participants who died from any cause was reported. The results are reported from second interim analysis, which deemed to be the confirmatory.
From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
Overall Survival: Second Interim Analysis (Co-primary Endpoint)
Ramy czasowe: From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
OS was defined as the time from the date of randomization to the date of death from any cause. The median duration of OS was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley. The results are reported from second interim analysis, which deemed to be the confirmatory.
From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
Percentage of Participants Who Died: Final Analysis
Ramy czasowe: From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
The percentage of participants who died from any cause was reported. The results reported are from the final analysis. The final analysis is descriptive.
From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
Overall Survival: Final Analysis
Ramy czasowe: From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
OS was defined as the time from the date of randomization to the date of death from any cause. The median duration of OS was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley. The results reported are from the final analysis. The final analysis is descriptive.
From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
Percentage of Participants Who Were Alive at Year 1
Ramy czasowe: Year 1
1 year survival was defined as the percentage of participants alive 1 year after starting treatment. The results reported are from the final analysis.
Year 1
Percentage of Participants Who Were Alive at Year 2
Ramy czasowe: Year 2
2 year survival was defined as the percentage of participants alive 2 years after starting treatment. The results reported are from the final analysis.
Year 2

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Percentage of Participants With PD or Death as Assessed by the Investigator
Ramy czasowe: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
PD was assessed by the investigator using modified RECIST. All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. PD for TLs was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. PD for non-TLs was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. The percentage of participants who died or experienced PD by Investigator was reported.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
PFS as Assessed by the Investigator
Ramy czasowe: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Tumor response was assessed by the investigator according to modified RECIST. All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. PD for TLs was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. PD for non-TLs was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. PFS was defined as the time from randomization to first documented PD by Investigator or death from any cause (whichever occurred earlier). The median duration of PFS was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Percentage of Participants With Objective Response (OR) as Assessed by an IRC
Ramy czasowe: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Tumor response was assessed by an IRC according to modified RECIST. OR was defined as the percentage of participants with a complete response (CR) or partial response (PR). All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. For TLs, a CR was defined as the disappearance of all TLs and a PR was defined as >/= 30% decrease in the SLD of TLs, taking as reference the baseline SLD. For non-TLs, a CR was defined as the disappearance of all non-TLs and a PR was defined as the persistence of 1 or more non-TLs. Confirmation of response at a consecutive tumor assessment at least 4 weeks apart was required. Participants without a post-baseline tumor assessment were considered non-responders. The percentage of participants with CR or PR by IRC was reported. The 95% CI was computed using Blyth-Still Casella exact CI method.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Duration of Objective Response (DOR) as Assessed by an IRC
Ramy czasowe: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Tumor response was assessed by an IRC according to modified RECIST. DOR was defined as the time from first documented OR to first documented PD or death from any cause, whichever occurred earlier. OR was defined as a CR or PR determined on 2 consecutive tumor assessments at least 4 weeks apart. For TLs, CR was defined as the disappearance of all TLs; PR was defined as >/=30% decrease in the SLD of TLs, taking as reference the baseline SLD; and PD was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, CR was defined as the disappearance of all non-TLs; PR was defined as the persistence of 1 or more non-TLs; and PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. The 95% CI was computed using the method of Brookmeyer and Crowley.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Percentage of Participants With Clinical Benefit as Assessed by an IRC
Ramy czasowe: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Tumor response was assessed by an IRC according to modified RECIST. Participants were considered as experienced clinical benefit if they had an OR or maintained stable disease (SD) for at least 6 months from randomization. OR: CR or PR determined on 2 consecutive tumor assessments >/=4 weeks apart. For TLs, CR: disappearance of all TLs; PR: >/=30% decrease in the SLD of TLs, taking as reference the baseline SLD; PD: >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or appearance of 1 or more new lesions; and SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. For non-TLs, CR: disappearance of all non-TLs; PR/SD: persistence of 1 or more non-TLs; and PD: appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Participants without a post-baseline tumor assessment were considered non-responders. The 95% CI was computed using Blyth-Still Casella exact CI method.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Percentage of Participants With Treatment Failure
Ramy czasowe: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Treatment failure was defined as discontinuation of treatment for any reason, including PD (per investigator review), treatment toxicity, or death from any cause. For "Lapatinib + Capecitabine" arm, a participant was considered as treatment failure only if both drugs were discontinued. For TLs, PD was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Percentage of participants with treatment failure was reported.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Time to Treatment Failure
Ramy czasowe: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Time to treatment failure was defined as the time from randomization to discontinuation of treatment for any reason, including PD (per investigator review), treatment toxicity, or death from any cause. For "Lapatinib + Capecitabine" arm, a participant was considered as treatment failure only if both drugs were discontinued with treatment failure date as the later of the 2 discontinuation dates. For TLs, PD was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. The median time to treatment failure was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Percentage of Participants With Symptom Progression
Ramy czasowe: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Symptom progression was defined as the documentation of a >/= 5-point decrease from baseline in the scoring of responses as measured by the Functional Assessment of Cancer Therapy-for participants with Breast Cancer (FACT-B) questionnaire with the Trial Outcomes Index-Physical/Functional/Breast (TOI-PFB) subscale. The FACT-B TOI-PFB subscale contained 24 items from 3 subsections of the FACT-B questionnaire: Physical well-being, functional well-being, and additional concerns for breast cancer participants (breast cancer subscale [BCS]). All items in the questionnaire were rated by the participant on a 5-point scale ranging from 0 ("not at all") to 4 ("very much"). The total score ranged from 0 to 96 with higher score indicating better perceived quality of life. The percentage of participants with symptom progression was reported.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Time to Symptom Progression
Ramy czasowe: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Time to symptom progression was defined as the time from randomization to the first documentation of a >/= 5-point decrease from baseline in the scoring of responses as measured by the FACT-B questionnaire with the TOI-PFB subscale. The FACT-B TOI-PFB subscale contained 24 items from 3 subsections of the FACT-B questionnaire: Physical well-being, functional well-being, and additional concerns for breast cancer participants (BCS). All items in the questionnaire were rated by the participant on a 5-point scale ranging from 0 ("not at all") to 4 ("very much"). The total score ranged from 0 to 96 with higher score indicating better perceived quality of life. The median time to symptom progression was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Hoffmann-La Roche

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Publikacje ogólne

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów

1 lutego 2009

Zakończenie podstawowe (Rzeczywisty)

1 lipca 2012

Ukończenie studiów (Rzeczywisty)

1 września 2015

Daty rejestracji na studia

Pierwszy przesłany

22 stycznia 2009

Pierwszy przesłany, który spełnia kryteria kontroli jakości

22 stycznia 2009

Pierwszy wysłany (Oszacować)

26 stycznia 2009

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Oszacować)

31 października 2016

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

10 września 2016

Ostatnia weryfikacja

1 września 2016

Więcej informacji

Terminy związane z tym badaniem

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • BO21977
  • TDM4370g (Inny identyfikator: Genentech)

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Badania kliniczne na Rak piersi

Badania kliniczne na Trastuzumab emtansine

Wyszukaj podobne próby

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

CROs by country

CROs in Austria

Warunki

Rzadkie choroby

Interwencje lekowe

Suplementy diety

Sponsor / Współpracownicy

Lokalizacje

Subskrybuj